Cureline Group’s Full Range of Research Services Now Available Through Scientist.com
25.7.2023 14:55:00 EEST | Business Wire | Press release
Cureline Group, an industry pioneer in precision and translational medicine, today announced its plans to showcase its full spectrum of research products and services on Scientist.com, the premier preclinical research marketplace for the biopharma sector. Biopharma researchers utilizing Scientist.com can now quickly and economically access essential services such as biobanking (including collection, processing, storage and retrieval of biological samples), human sample validation (including biomarker identification and verification), preclinical animal services and preclinical project management (protocol design, study execution and data analysis), histopathology, digital pathology and other lab services that are critical to accelerating drug discovery and development.
“We are excited to continue our longstanding partnership with Scientist.com, which has helped us connect with many biopharma researchers at top pharma and biotech companies,” stated Dr. Olga Potapova, Founder and CEO of the Cureline Group. “With our 20 years of translational CRO experience, we want to make it easy for any industry or academic scientist to access the many innovative tools and technologies and regulatory expertise that we’ve brought together under one roof.”
The Cureline Group, comprised of an array of companies including Cureline, Inc., Cureline BioPathology (CBP), Cureline Molecular Services (CMS), Cureline Baltic UAB, DolceRx Baltika UAB and the newly formed Memel Biotech, offers an extensive portfolio of ISO-certified, CAP-compliant preclinical research and biomarker/companion diagnostics services. Clinical expertise will be delivered by the recent strategic partnership of palleos healthcare (Germany) and Cureline. Offering clients a full-service approach can help reduce complexity and save time.
“The Cureline Group has evolved into a one-stop shop for high-quality research services in the preclinical research and biomarker/companion diagnostic spaces,” stated Kevin Lustig, PhD, Founder and CEO at Scientist.com. "We are delighted to feature their services on Scientist.com’s fast-growing, AI-powered marketplace."
About Cureline, Inc., and the Cureline Group of companies:
As a global leader in commercial biobanking and translational research services celebrating 20 years in business in 2023, we have completed over 5,000 projects for 850 clients. Cureline, Inc., (USA) together with other Cureline Group companies, is a global precision and translational medicine contract research organization (CRO) providing biobanking and HBS services in the preclinical phase and companion diagnostics development for clinical trials to the biopharmaceutical industry. Cureline Group management are experts in global regulatory affairs, custom protocol biobanking, histopathology & digital pathology, molecular and cellular lab services, small animal studies and cell and gene therapy (ATMP) solutions. Since 2021, UAB Cureline Baltic (Lithuania) is servicing our clients' needs in animal toxicology and preclinical efficacy studies in small animals with a focus on metastatic cancer, immunology and microbiota models. Starting in 2024, Memel Biotech UAB (Lithuania) will be providing GMP CDMO service for the ATMP clinical research community.
Visit http://www.cureline.com/ to learn more.
About Scientist.com
Scientist.com's mission is to empower and connect scientists worldwide. The company's AI-powered research platform combines a custom-built, cloud native technology stack with white-glove customer and scientific support to enable scientists to run more innovative experiments in less time and at lower cost. Scientist.com leverages internally developed machine learning models to provide actionable insights that improve operational efficiency and effective research management. Scientist.com connects the world's top pharmaceutical companies, biotechnology companies and the US National Institutes of Health (NIH) to the world's largest network of scientific suppliers.
Visit Scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram
About palleos healthcare GmbH
palleos healthcare is a full-service CRO with 50 highly experienced employees covering Phase I – IV drug and medical device clinical research services in central Europe. More than 10,000 patients at 300 sites were treated in various trials and indications with the results published in highly ranked journals. palleos healthcare also offers drug development consulting services for biotech and medtech companies, streamlining their early and pre-clinical development decisive milestones, allowing earlier and more efficient exit and reinvestment. As a certified partner with best-in-class players in the digital life science field (Veeva, Medidata, etc.), palleos healthcare offers cloud-based services for data management and decentralized clinical trials.
Visit www.palleos.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230725851885/en/
Contact information
Media Contact:
Olga Potapova, CEO, The Cureline Group
+1 415-468-6400 ext. 221
olga-potapova@cureline.com
Sean Preci, Sr. Director, Marketing & Content, Scientist.com
+1 858 771-3813 ext. 187
marketing@scientist.com
Heiko Bergmann, VP Sales & Strategy, palleos healthcare GmbH
+49 611 950 190 0 ext. 50
heiko.bergmann@palleos.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
euroAtlantic Airways Appoints Pauls Calitis as CEO to Lead Next Phase of Growth5.5.2026 10:00:00 EEST | Press release
euroAtlantic Airways (“EAA”), a leading global provider of passenger widebody aircraft wet-leasing and charter services, and Njord Partners portfolio company, is pleased to announce the appointment of Pauls Calitis as Chief Executive Officer, effective 18 May 2026. Pauls will succeed Stewart Higginson, who has served as CEO since early 2024 and who will assume the role of Non-Executive Chairman of the Board. The appointment marks the next phase of the company’s development under Njord Partners. Pauls brings more than three decades of expertise in the aviation industry, most recently serving as Chief Operating Officer and Executive Board Member at airBaltic, having also held the role of Interim Chief Executive Officer in 2025. Over his career progressing from pilot to senior executive leadership, he played a central role in the airline’s development and transformation into one of Europe’s most efficient and respected carriers. His leadership helped establish the airline as a benchmark f
Wolters Kluwer advances Libra legal AI workspace with enhanced contract review and integrated workflows5.5.2026 10:00:00 EEST | Press release
Wolters Kluwer Legal & Regulatory today announced a new release of Libra by Wolters Kluwer, its legal AI workspace integrating major workflow capabilities with trusted, expert-generated content. The update introduces significant advancements in contract review, workflow integration and usability, and strengthens Libra’s role as an all-in-one platform where legal professionals can research, draft, review and analyze in a connected and integrated environment. Based on customer feedback, the new release focuses on four key areas: stronger organization across projects, a more powerful and flexible review experience, deeper integration between chat and structured workflows, and a refreshed visual and interaction design. Together, these enhancements respond directly to user feedback and reflect Wolters Kluwer’s focus on user-centric, trusted AI. “With this release, we are making a clear step forward in how legal professionals work with AI in practice,” said Viktor von Essen, CEO of Libra by
SWISSto12 Partners With German Consortium HPS/LSS on First-Ever Unfurling Antenna Reflector to Be Built in Europe for Commercial GEO Telecommunications Satellite5.5.2026 10:00:00 EEST | Press release
SWISSto12 announced today a major contract with German high-performance space subsystem providersHPS/LSS. The Munich-based consortium will provide a large deployable reflector subsystem (LDRS) for the NEASTAR-1 mission, built on HummingSat, enabling the world’s first direct-to-device media broadcasting capabilities from geostationary orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505082353/en/ SWISSto12 enables world-first approach to GEO-based D2D connectivity, leveraging an unfurling antenna, in collaboration with HPS/LSS The German-led antenna reflector subsystem is the result of more than 15 years of development under the European Space Agency’s (ESA) Advanced Research in Telecommunications (ARTES) programme, ESA’s Earth Observation Technology Development activities, and the EU’s Horizon 2020 programme. The contract for the NEASTAR-1-LDRS is co-funded by ESA, with core funding from the German Space Agency withi
SES’s O3b mPOWER Satellite Network to Connect Seven New Petrobras FPSOs5.5.2026 09:50:00 EEST | Press release
SES, a leading space solutions company, will provide service on its high-capacity medium-Earth orbit (MEO) satellite network, O3b mPOWER, to Petrobras, the Brazilian state-owned oil company, to connect multiple new Floating Production, Storage and Offloading systems (FPSOs). The projects will go into operation in the coming years, expanding Petrobras’ oil and gas production capacity to meet national energy needs and contribute to global oil markets. FPSOs are modern and efficient oil production platforms, responsible for processing, collecting, storing, and transferring oil to shuttle tankers, directly from subsea wells in deepwater fields. FPSOs offer the flexibility, capacity, and operational resilience needed to sustain large-scale offshore production in remote and challenging environments. Brazil is home to the majority of the offshore projects under development worldwide, and Petrobras is one of the largest FPSO operators on the planet, responsible for most of the country’s oil an
Regnology Completes Acquisition of Moody’s Regulatory Reporting & Asset and Liability Management (ALM) Solutions5.5.2026 09:00:00 EEST | Press release
Regnology, a global provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the completion of its acquisition of Moody’s Regulatory Reporting & ALM Solutions business. The transaction expands Regnology’s solution portfolio with Moody’s comprehensive capabilities covering Basel III compliance, IFRS 9 impairment, large‑bank asset and liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting. The transaction closes at a pivotal inflection point. Financial institutions face intensifying regulatory scrutiny, growing data complexity, and rising expectations for governance and auditability, while advances in artificial intelligence are creating new opportunities to modernize control frameworks and operating models. Regnology is responding by accelerating its Straight-Through Reporting (STR) vision and leveraging the combined capabilities of the transaction to deliver more resilient, transparen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom